Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. An International, Open-Label, Uncontrolled, Single-Arm, Multicenter, Phase 2 Trial
Condition: Neuroblastoma Interventions: Drug: Naxitamab; Drug: GM-CSF; Drug: Isotretinoin Sponsor: Y-mAbs Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials